Filing identity and reporting period
The supplied filing is a Form 10-Q for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc. It covers the quarter and six months ended September 30, 2014 (the second quarter of Oculus’s fiscal 2015, which began April 1, 2014). The filing’s unaudited interim statements are in thousands of dollars unless otherwise noted.
Business context and financial results
Oculus develops and sells dermatology and advanced tissue-care products based on its Microcyn technology, as well as laboratory testing services. The company reported a strategic focus on dermatology. It had U.S. medical-device clearances for certain products, but said it did not have the regulatory approvals needed to market Microcyn as a drug.
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue, 2014; 2013 | $3.264 million; $4.089 million | $6.656 million; $7.461 million |
| Gross profit, 2014; 2013 | $1.732 million; $2.705 million | $3.638 million; $4.905 million |
| Operating loss, 2014; 2013 | $1.544 million; $1.271 million | $3.058 million; $2.397 million |
| Net loss, 2014; 2013 | $718,000; $1.399 million | $788,000; $3.111 million |
| Net loss per share, 2014; 2013 | $0.08; $0.21 | $0.09; $0.47 |
Revenue fell 20% in the quarter and 11% for the half year. Product gross margin, including licensing revenue, was 55% versus 69% in the quarter and 57% versus 68% for the half year. Management attributed weaker margins mainly to lower U.S. animal-healthcare sales. The improved net loss included noncash gains from lower warrant derivative liabilities of $841,000 for the quarter and $2.319 million for the half year; the six-month operating loss nevertheless increased year over year.
Cash, liquidity, debt, and capital
- Cash and cash equivalents were $3.549 million at September 30, 2014, down from $5.480 million at March 31, 2014. Working capital was $2.830 million, compared with $1.970 million.
- Operating activities used $3.009 million of cash in the six months, versus $2.454 million in the comparable 2013 period. Investing activities provided $23,000; financing activities provided $1.074 million, including $1.213 million of net ATM equity proceeds and $139,000 of debt principal payments. Cash declined by $1.931 million overall.
- Debt was minimal at quarter-end: $8,000 current and no long-term portion. The filing says the Venture Lending and Leasing debt and interest had been settled in December 2013.
- Total assets were $18.394 million, including a $10.150 million investment in 2 million Ruthigen shares carried at cost. Derivative liabilities were $856,000, down from $3.175 million at March 31, 2014.
- The ATM program permitted up to $9.159 million in gross share sales. By September 30, sales had generated $1.213 million net; by November 5, 2014, the filing reported $1.399 million net proceeds from 467,934 shares. Common shares outstanding were 8,585,382 at September 30 and 8,660,580 at November 12.
Material changes, outlook, and risks
- Distribution transition: Innovacyn notified Oculus that it planned to transition to another supplier over the following year. Related revenue was $459,000 in the quarter and $987,000 in the half year, compared with $1.289 million and $2.030 million, respectively, in the prior-year periods. Management expected further declines and said replacement partners might not restore prior revenue levels.
- Regional performance: U.S. product and license revenue declined 48% in the quarter and 38% in the half year. Mexico increased 14% and 8%, respectively; Europe and the rest of the world declined 8% in the quarter but increased 21% for the half year. Service revenue also decreased.
- Concentration: For the six months, one customer represented 45% of net revenue and another 15%. At September 30, one customer accounted for 56% of net accounts receivable and another 11%.
- Management outlook: Oculus expected research and development expense to decrease overall in coming quarters as Ruthigen-related spending fell, while anticipating increased development spending for tissue-care and dermatology products. It expected selling, general and administrative expense to rise as it expanded its direct sales force. No numerical revenue or earnings guidance was provided.
- Going concern: Management expected continuing losses and stated that additional capital was required to fund development, market penetration, and ongoing operations. No new financing commitment had been secured, and availability on acceptable terms was uncertain. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern; the statements contain no related adjustments.
- Other risks and contingencies: The company reported no material change to previously disclosed risk factors and characterized ordinary-course legal matters as currently insignificant, while noting potential adverse effects. Four executive employment agreements carried potential severance of $1.130 million. A stockholder vote was scheduled for December 4, 2014, on increasing authorized common shares from 14,285,715 to 30 million.
Important facts for investors to verify
- Confirm the correct issuer and period: the filing is for Oculus Innovative Sciences, not Sonoma Pharmaceuticals.
- Assess cash runway and financing needs against the going-concern warning, operating cash use, and available ATM capacity.
- Track Innovacyn’s transition and whether new distribution partners replace lost animal-healthcare and OTC revenue.
- Evaluate customer concentration, the collection of significant receivables, and dependence on More Pharma; its receivable balance was $1.201 million.
- Separate recurring operating performance from the noncash warrant revaluation gain that materially reduced reported net loss.
- Review the Ruthigen investment’s recoverability and potential dilution from equity issuance and any increase in authorized shares.